We are live on ! Find out more
GRI

GRI Bio
GRI

4 hedge funds and large institutions have $15.5K invested in GRI Bio in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

1.59% less ownership

Funds ownership: 2.51% → 0.92% (-1.6%)

43% less funds holding

Funds holding: 7 → 4 (-3)

92% less capital invested

Capital invested by funds: $185K → $15.5K (-$170K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$9.57K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$63.1K
2
VF
Virtu Financial
New York
-$25K
3
UBS Group
UBS Group
Switzerland
-$19.6K
4
TSS
Two Sigma Securities
New York
-$13.1K

GRI Hedge Fund Activity: Q1 2025 in Review

4 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q1 2025, worth a combined $15.5K — down 92% from $185K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of GRI and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $9.57K. The largest seller was Geode Capital Management, exiting entirely with an estimated $63.1K sold.

  • 4 institutional investors held GRI Bio (GRI) as of Q1 2025, down from 7 in Q4 2024.
  • Funds reported $15.5K of GRI Bio stock for Q1 2025, down 92% quarter-over-quarter.
  • 0 funds opened new GRI Bio positions in Q1 2025 and 3 closed out, a net change of -3 holders.
  • The largest GRI Bio buyer in Q1 2025 was Tower Research Capital (TRC), an estimated $9.57K added.
  • The largest GRI Bio seller in Q1 2025 was Geode Capital Management, an estimated $63.1K sold.

Based on aggregated 13F filings for Q1 2025.